Correlation Between Biomarin Pharmaceutical and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Biomarin Pharmaceutical and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biomarin Pharmaceutical and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biomarin Pharmaceutical and Blueprint Medicines Corp, you can compare the effects of market volatilities on Biomarin Pharmaceutical and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biomarin Pharmaceutical with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biomarin Pharmaceutical and Blueprint Medicines.
Diversification Opportunities for Biomarin Pharmaceutical and Blueprint Medicines
0.02 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Biomarin and Blueprint is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Biomarin Pharmaceutical and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Biomarin Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biomarin Pharmaceutical are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Biomarin Pharmaceutical i.e., Biomarin Pharmaceutical and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Biomarin Pharmaceutical and Blueprint Medicines
Given the investment horizon of 90 days Biomarin Pharmaceutical is expected to under-perform the Blueprint Medicines. But the stock apears to be less risky and, when comparing its historical volatility, Biomarin Pharmaceutical is 2.07 times less risky than Blueprint Medicines. The stock trades about -0.28 of its potential returns per unit of risk. The Blueprint Medicines Corp is currently generating about 0.22 of returns per unit of risk over similar time horizon. If you would invest 8,440 in Blueprint Medicines Corp on August 24, 2024 and sell it today you would earn a total of 1,317 from holding Blueprint Medicines Corp or generate 15.6% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Biomarin Pharmaceutical vs. Blueprint Medicines Corp
Performance |
| Timeline |
| Biomarin Pharmaceutical |
| Blueprint Medicines Corp |
Biomarin Pharmaceutical and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Biomarin Pharmaceutical and Blueprint Medicines
The main advantage of trading using opposite Biomarin Pharmaceutical and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biomarin Pharmaceutical position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| Biomarin Pharmaceutical vs. Alnylam Pharmaceuticals | Biomarin Pharmaceutical vs. Exelixis | Biomarin Pharmaceutical vs. Halozyme Therapeutics | Biomarin Pharmaceutical vs. Arrowhead Pharmaceuticals |
| Blueprint Medicines vs. Lyra Therapeutics | Blueprint Medicines vs. Hookipa Pharma | Blueprint Medicines vs. Cingulate Warrants | Blueprint Medicines vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Complementary Tools
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |